Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Review Article Volume 3 Issue 12

COVID-19 and Neurology. A Viewpoint

Gabriel Abudinén Adauy*

Neurologist, Neurology and Neurosurgery Department, Hospital Clínico Universidad de Chile, Santiago, Chile

*Corresponding Author: Gabriel Abudinén Adauy, Neurologist, Neurology and Neurosurgery Department, Hospital Clínico Universidad de Chile, Santiago, Chile.

Received: October 27, 2020; Published: November 27, 2020

×

Abstract

  During this last time we have had to learn and investigate this new strain of coronavirus, which not only affects the respiratory tract, but also produces a systemic affection of different organs through diffuse endothellopathy and a severe systemic inflammatory response. In relation to the affection of the central nervous system, there is a direct relationship or neurotropism, through the receptors of the type 2 angiotensin converting enzyme (ACE2). This review tries to explain the neurological relationship and SARS-COV 2.

Keywords: Epidemiology; Neurology; SARS; COVID-19; Embolism Thrombosis

×

References

  1. Zhang G., et al. “Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China”. Journal of Clinical Virology 127 (2020): 104364.
  2. Richardson S., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area”. Journal of the American Medical Association 20 (2020): 2052-2059.
  3. Reportes Epidemiológicos de la Sociedad Chilena de Medicina Intensiva (2020).
  4. , et al. “Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor”. Pharmacological Research 14 (2020): 104833.
  5. Hoffmann N., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 181 (2020): 1-10.
  6. Tang X., et al. “On the origin and continuing evolution of SARS-CoV-2”. National Science6 (2020): 1012-1023.
  7. Lipworth B., et al. “Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection”. The Journal of Allergy and Clinical Immunology: In Practice6 (2020): 1798-1801.
  8. Rizo P., et al. “COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?”. Basic Research on Cardiology3 (2020): 31.
  9. Ranucci M., et al. “The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome”. Journal of Thrombosis and Haemostasis (2020).
  10. , et al. “Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19”. Military Medical Research 7 (2020): 19.
  11. Yan R., et al. “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2”. Science 6485 (2020): 1444-1448.
  12. Spinato G., et al. “Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection”. Journal of the American Medical Association20 (2020): 2089-2090.
  13. Baig A., et al. “Evidence of the COVID-19 Virus Targeting the CNS: TissueDistribution, Host−Virus Interaction, and Proposed Neurotropic mechanism”. ACS Chemical Neuroscience7 (2020): 995-998.
  14. Helms J., et al. “Neurologic Features in Severe SARS-CoV-2 Infection”. The New England Journal of Medicine 382 (2020): 2268-2270.
  15. Aggarwal G., et al. “Cerebrovascular Disease is Associated with an Increased Disease Severity in Patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature”. International Journal of Stoke4 (2020): 385-389.
  16. Toscano G., et al. “Guillain–Barré Syndrome Associated with SARS-CoV-2”. The New England Journal of Medicine 382 (2020): 2574-2576.
  17. Zhao K., et al. “Acute myelitis after SARS-CoV-2 infection: a case report”. medRxiv (2020).
  18. Morigushi T., et al. “Meningitis/Encephalitis associated with SARS-coronavirus 2”. International Journal of Infectious Diseases (2020).
  19. Poyiadji N., et al. “COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI”. Radiology2 (2020).
×

Citation

Citation: Gabriel Abudinén Adauy. “COVID-19 and Neurology. A Viewpoint". Acta Scientific Neurology 3.11 (2020): 42-44.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.844

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US